SCHEMBL24188144

SCHEMBL24188144

O=C1CCc2nc(-c3ccccc3Cl)[nH]c2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GUSB P08236 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.44
▸ KDM4E B2RXH2 4/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ GPR55 Q9Y2T6 1/20 0.44
▸ PTGES O14684 7/20 0.42
▸ PIM1 P11309 3/20 0.40
▸ CSNK2A2 P19784 3/20 0.40
▸ CSNK2B P67870 3/20 0.40
▸ PIM3 Q86V86 3/20 0.40
▸ PIM2 Q9P1W9 3/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ MGAM O43451 1/20 0.40
▸ GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31288988 0.79 ALDH1A1 (0.49) GUSBALDH1A1KDM4ENPC1RAB9A
SCHEMBL24187953 0.75 PDCD1 (0.62) GUSBALDH1A1KDM4ENPC1RAB9A
SCHEMBL24188247 0.72 PDCD1 (0.49) GUSBALDH1A1KDM4ENPC1RAB9A
SCHEMBL23849970 0.71 KDR (0.48) —
SCHEMBL24188487 0.70 KDM4E (0.40) GUSBALDH1A1KDM4ENPC1RAB9A
SCHEMBL24188365 0.69 KDM4E (0.40) GUSBALDH1A1KDM4ENPC1RAB9A
SCHEMBL4738751 0.69 ALDH1A1 (0.53) GUSBALDH1A1KDM4ENPC1RAB9A
SCHEMBL4738750 0.69 GUSB (0.45) GUSBALDH1A1KDM4ENPC1RAB9A
SCHEMBL31288991 0.68 KDR (0.40) GUSBALDH1A1KDM4ENPC1RAB9A
SCHEMBL24188233 0.67 KDR (0.48) ALDH1A1KDM4ENPC1RAB9AGPR55

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220009935-A1 INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS NEW YORK UNIVERSITY 2022-01-13 — — US disclosed
CN-113316577-A GLi1 inhibitors as therapeutic agents 纽约大学 2021-08-27 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220009935-A1 INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS GLI1, GLI2, SHH GUSB 1555/4885ALDH1A1 1281/4885KDM4E 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback